Search

Crinetics Pharmaceuticals Inc

Open

SectorHealthcare

83.79 -0.17

Overview

Share price change

24h

Current

Min

83.64

Max

83.95

Key metrics

By Trading Economics

Income

-5M

-128M

Sales

6.8M

11M

EPS

-1.23

Profit margin

-1,191.029

Employees

594

EBITDA

-5M

-127M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+2% upside

Dividends

By Acuity

Next Earnings

4 Aug 2026

Market Stats

By TradingEconomics

Market Cap

4.5B

8.9B

Previous open

83.96

Previous close

83.79

News Sentiment

By Acuity

67%

33%

294 / 340 Healthcare

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jul 2026, 23:56 UTC

News

Industrial Logistics Properties Trust shares declined after second-quarter results missed expectations, reporting a loss of -$0.22 per share and revenue of $114.12 million.

29 Jul 2026, 23:56 UTC

News

Adobe shares rose after-market, reaching about $263.62. Elevated options volume and a lower put/call ratio reflect bullish sentiment.

29 Jul 2026, 23:56 UTC

News

Logitech International SA's quarterly report filing has led to shares trading higher in after-market hours, reflecting increased investor interest.

29 Jul 2026, 23:52 UTC

Social Media
News

Robinhood Markets reported record Q2 revenue of $1.31 billion but shares are lower in after-market trading due to a drop in cryptocurrency revenue and revised expense outlook.

29 Jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Hecla Mining reported positive Q2 exploration results, extending high-grade mineralization at Keno Hill and Midas. Shares are higher in after-market trading.

29 Jul 2026, 23:51 UTC

Social Media
News

PennyMac Mortgage Investment Trust's Q2 EPS of $0.23 missed estimates, with revenue at $73 million. Shares are trading lower in after-market hours.

29 Jul 2026, 23:51 UTC

News

Five9 Inc will join the S&P SmallCap 600 index, effective August 3, 2026. Shares are higher in after-market trading following the announcement.

29 Jul 2026, 23:51 UTC

News

General Motors Co shares declined in after-market hours as Ford's strong earnings and guidance overshadowed its outlook amid broader market pressures.

29 Jul 2026, 23:51 UTC

Social Media
News

American Water Works reported strong Q2 earnings and revenue but shares declined slightly in after-market hours, reflecting broader market trends.

29 Jul 2026, 23:46 UTC

Social Media
News

DoorDash Inc launches DoorDash Air, a new drone delivery unit. Shares are higher in after-market trading, continuing recent upward momentum.

29 Jul 2026, 23:46 UTC

News

Avis Budget Group reported second-quarter earnings below expectations, with revenue at $3 billion and EPS of $0.98. Shares are lower in after-market hours.

29 Jul 2026, 23:46 UTC

News
Correlated Moves

Entegris Inc. announced board changes, with Bertrand Loy retiring in 2026. Shares are higher in after-market hours, reflecting a broader Nasdaq 100 increase.

29 Jul 2026, 23:41 UTC

News

Claros Mortgage Trust reported a second-quarter net loss of $255.4 million, contributing to a decline in after-market trading. Shares are lower.

29 Jul 2026, 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

29 Jul 2026, 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

29 Jul 2026, 23:41 UTC

News

Churchill Downs shares fell after reporting Q2 adjusted EPS of $3.45, slightly missing estimates, and announcing plans to explore property sales.

29 Jul 2026, 23:41 UTC

Social Media
News

Meta Platforms reported second-quarter earnings below expectations, with net income declining to $15.85 billion. Shares fell sharply in after-market trading amid rising costs.

29 Jul 2026, 23:41 UTC

Social Media
News

Qualcomm Inc shares fell in after-market trading following weaker-than-expected guidance and a profit decline in its third-quarter fiscal 2026 results.

29 Jul 2026, 23:41 UTC

Social Media
News

Modine Manufacturing reported first-quarter net income of $73.9 million, but shares declined in after-market trading following mixed results and revenue that missed estimates.

29 Jul 2026, 23:36 UTC

News

Antero Resources shares are lower in after-market trading following a second-quarter earnings report that included an adjusted EPS miss and mixed operational results.

29 Jul 2026, 23:36 UTC

News

Peabody Energy announced a quarterly dividend of $0.075 per share after reporting $1 billion in revenue, despite a net loss of $90.6 million. Shares rose in after-market trading.

29 Jul 2026, 23:32 UTC

News

Invitation Homes reported strong Q2 results, with net income rising to $218.2 million. Shares are trading higher in after-market hours following the earnings report.

29 Jul 2026, 23:32 UTC

News

AXT Inc secures an $87 million supply agreement with Lumentum for indium phosphide wafers, boosting its strategic position in the semiconductor market during after-market hours.

29 Jul 2026, 23:31 UTC

News

Saia Inc shares are higher in after-market trading as the company prepares to report earnings. It exceeded revenue expectations with $806.2 million last session.

29 Jul 2026, 23:31 UTC

News

DMC Global Inc reported second-quarter sales of $157 million, exceeding estimates. Shares are trading higher in after-market hours following the results.

29 Jul 2026, 23:31 UTC

Social Media
News

Lam Research Corp reported strong second-quarter earnings, with adjusted EPS of $1.82 and optimistic guidance for Q3, driving shares higher in after-market trading.

29 Jul 2026, 23:31 UTC

News

iShares 7-10 Year Treasury Bond ETF trades lower in after-hours, reflecting market caution amid geopolitical tensions and concerns about rising interest rates and inflation.

29 Jul 2026, 23:31 UTC

News

Vanguard Total Bond Market ETF declines in after-market trading amid rising geopolitical tensions and concerns over inflation and interest rates affecting market sentiment.

29 Jul 2026, 23:31 UTC

News

RenaissanceRe Holdings increased its share buyback program to $750 million and declared a quarterly dividend of $0.41, driving shares higher in after-market trading.

29 Jul 2026, 23:26 UTC

News

Ford Motor Co reported adjusted earnings of $0.42 per share, raising its 2026 guidance and prompting shares to rise in after-market trading.

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

2% upside

12 Months Forecast

Average 85.56 USD  2%

High 95 USD

Low 80 USD

Based on 14 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

2

Buy

12

Hold

0

Sell

Sentiment

By Acuity

294 / 340 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat